Sudarshan Chemical Industries Sets Q2 FY27 Review for November 6

Sudarshan Chemical Industries Limited is scheduled to review unaudited Q2 FY27 results for the quarter and half year ended September 30, 2026, on November 6, with management due to address analysts at 4:00 p.m. IST. The meeting will provide the company’s next formal update after its reported Q1 FY27 pigment business revenue of Rs 2,605 crore.

When will Sudarshan Chemical Industries announce Q2 FY27 results?

Sudarshan Chemical Industries will hold a board meeting on November 6, 2026, to approve unaudited standalone and consolidated financial results for Q2 FY27 and the first half of FY27. The reported period ended September 30, 2026.

The company has also scheduled an analyst meeting on the same day at 4:00 p.m. IST. The event, hosted by 360 ONE Capital Market Research, will be conducted through video conference and webcast. The announcement identifies Chairman Rajesh Rathi and Chief Financial Officer Nilkanth Natu among the management representatives expected to present.

The company’s disclosures describe the event as a discussion of its latest financial performance and outlook. No Q2 FY27 financial figures, including revenue, profit, margin or segment performance, were included in the available announcement before the scheduled board review.

The results are relevant for shareholders because they will cover both the July-September quarter and the six months from April through September. The standalone and consolidated disclosures will allow investors to assess the company’s reported performance across its operations and group structure.

What will management discuss at the November 6 analyst meet?

Sudarshan Chemical Industries will discuss unaudited Q2 FY27 and half-year results at the analyst meet scheduled for 4:00 p.m. IST. Management’s participation means the session is expected to accompany the financial disclosure approved by the board, rather than being a separate operational announcement.

The company manufactures and sells organic, inorganic and effect pigments, performance colorants, pearlescent pigments and specialty chemicals in India and international markets. This business mix makes the quarterly update important for tracking both the pigments portfolio and broader specialty chemical activities.

The available materials also indicate that the company has made investor presentations and earnings-call documents available for earlier periods, including Q1 FY27, Q3 FY26, Q2 FY26 and Q1 FY26. The November 6 discussion will extend this reporting sequence with management commentary on the September quarter.

Investors will need to wait for the official results, presentation and call disclosures for details on quarterly trends. The pre-results intimation does not specify expected sales, profitability, volumes, pricing, cash flow, debt or capital expenditure.

What is Sudarshan Chemical Industries' recent financial context?

Sudarshan Chemical Industries reported pigment global revenue of Rs 2,605 crore and business EBITDA of Rs 257 crore in Q1 FY27, representing a business EBITDA margin of 9.8%, according to the company’s August 2026 investor presentation summary. These figures followed the integration of the Heubach acquisition.

The company has reaffirmed FY27 guidance for the acquired group of euro 700 million in sales and euro 35 million in EBITDA. This is guidance for the acquired group and should not be treated as a reported financial result for Sudarshan Chemical Industries’ full consolidated business.

The company has also stated a medium-term turnover target of more than Rs 12,000 crore. The target provides context for its focus on scale following the acquisition integration, although the materials provided do not set a specific deadline for achieving it.

For comparison, the latest quarterly figures shown in the supplied historical chart were for Q4 FY26, when revenue stood at Rs 2,800 crore and net profit was Rs 82 crore. The chart noted that Q1 FY27 figures were not yet included there, while the Q1 filing and presentation provided separate information.

Why do the Q2 FY27 results matter to investors?

The Q2 FY27 results matter because they will be the next reported measure of Sudarshan Chemical Industries’ financial performance after its Q1 update and continuing Heubach acquisition integration. The September-quarter disclosure can provide investors with reported numbers against which they can assess the company’s stated growth and profitability objectives.

The scheduled release also has relevance for investors following the acquired group’s FY27 guidance of euro 700 million in sales and euro 35 million in EBITDA. Any discussion of integration, operating performance or outlook during the analyst call will need to be read alongside the official financial statements and management presentation.

For the pigments and specialty chemicals industry, the update will add a current company-level data point on a business that serves domestic and international markets. However, the announcement alone does not establish the direction of demand, raw-material costs, pricing or sector-wide margins during the quarter.

The 4:00 p.m. management interaction provides a scheduled forum for shareholders and analysts to hear the company’s explanation of the released figures. Until results are formally published, conclusions on Q2 performance or changes in outlook would not be supported by the available disclosures.

Conclusion

Sudarshan Chemical Industries has set November 6 for its Q2 FY27 board review and analyst meeting, covering unaudited results for the quarter and half year ended September 30, 2026. The scheduled disclosure follows Q1 FY27 pigment global revenue of Rs 2,605 crore, business EBITDA of Rs 257 crore and a 9.8% margin.

The next items to watch are the approved standalone and consolidated results, the accompanying investor presentation and management’s comments at the 4:00 p.m. IST analyst meet. Investors can also assess whether the company reiterates or updates the acquired group’s FY27 guidance of euro 700 million in sales and euro 35 million in EBITDA.